Thursday, March 28, 2024

Creating liberating content

Oracle Corp’s (NYSE: ORCL)...

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15%...

RTX Corp (NYSE: RTX)...

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03...

GameStop Corp. (NYSE:GME) Quarter...

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after...

Advanced Micro Devices (NASDAQ:AMD)...

Shares of Advanced Micro Devices (NASDAQ:AMD) drops 0.38% in afterhours in last trading...
HomeBiotech-PharmaImara Inc (NASDAQ:...

Imara Inc (NASDAQ: IMRA) Decides To Merge Enliven Therapeutics Inc. In An All-Stock Transaction

Imara Inc (NASDAQ: IMRA) plunges over 6.07% in pre trading session on Monday as the firm decided to merge Enliven Therapeutics Inc. in an all-stock transaction. The combined company will focus on advancing Enliven’s pipeline of precision oncology product candidates.

Enliven Therapeutics, Inc. and Imara Inc. (IMRA) announced a formal merger agreement in which the businesses would be combined in an all-stock transaction. Enliven’s pipeline of precision oncology therapeutic candidates will be prioritized by the merged business.

Enliven also intends to raise approximately $165 million in a concurrent private financing co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences, and Commodore Capital, in support of the merger. OrbiMed, 5AM Ventures, Surveyor Capital, Cormorant Asset Management, Roche Venture Fund, Sheatree Capital, Boxer Capital, Logos Capital, and Janus Henderson Investors will also participate in the funding. The fundraising was oversubscribed, with fresh investor allocations accounting for more than 60% of the entire amount of the transaction, which is slated to conclude immediately before the merger’s completion.

After transaction expenditures, the merged business is estimated to have approximately $300 million in cash and cash equivalents at closure, based on the cash expected from both firms at close and the proceeds of the planned concurrent financing. The funds will be utilized to develop Enliven’s pipeline through various clinical milestones and to provide runway through early 2026. The merger and financing are expected to close in the first quarter of 2023, subject to both companies’ stockholder approval, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission (SEC) to register the shares of Imara common stock to be issued in connection with the merger, and the fulfillment of customary closing conditions.

The Co-Founder and CEO of Enliven, Sam Kintz stated that they are delighted to announce this merger with Imara, which comes at an important juncture for Enliven. They just started a Phase 1 clinical trial for ELVN-001 in adults with CML, and they aim to file an IND for ELVN-002 by the end of the year. They anticipate that this transaction will provide Enliven with funds to help them reach several critical milestones and explore the possibilities of their pipeline. They are excited to assist patients with cancer not just survive longer, but live better lives.

Oracle Corp’s (NYSE: ORCL) Cloud Business Faces Headwinds: What Lies Ahead

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15% or $15.21 to trade at $111.50 in pre trading session on...

RTX Corp (NYSE: RTX) Updates 2023-2025 Outlook amid Engine Part Challenge

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03 per share, bringing its current trading price to $77.45. The company,...

GameStop Corp. (NYSE:GME) Quarter Report: Resilience amidst Market Turbulence

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after the market closes today. Shares were slightly down in the pre-trading...

Continue reading

C3.ai Inc. (NYSE: AI) Short Seller Accuses Company of ‘Highly Aggressive Accounting’

Shares of C3.ai Inc. (NYSE: AI) inches down in pre trading session on Thursday as Kerrisdale Capital, a short seller, claimed that the business software firm has "severe accounting and transparency concerns." In a letter to Deloitte & Touche LLP,...

Walmart Inc. (NYSE: WMT) Aims to Cut 2,000 Workers at Five US E-Commerce Facilities

Walmart Inc. (NYSE: WMT) inches down in early trading session on Tuesday as the company would eliminate more than 2,000 workers at five US e-commerce facilities, as per Bloomberg. According to the report, which used regulatory filings, the layoffs...

BlackBerry Limited (NYSE: BB) Declares $900M Patent Sale to Malikie Innovations

BlackBerry Limited (NYSE: BB) drops around 2% in pre session on Monday as the business recently announced a new patent sale agreement for up to $900 million with Malikie Innovations Ltd, a division of the industry's top patent monetization...

Enjoy exclusive access to all of our content

Get an online subscription and you can unlock any article you come across.